profit from every $100 of sales.
$0$100
Silo Pharma
$1.84-3.66% today
+322.7% in 1 year
1-year low $0.361-year high $9.99
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Silo Pharma sold, what it kept, and what it did with the cash.
Sales went from $72,102 in 2022 to $72,102 in 2025, with -$4.23 million of profit last year.
SalesProfit
Silo Pharma vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Silo Pharma | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Silo Pharma's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 | |
| -4 | -4 | -5 | -4 | |
| -4 | -4 | -4 | -4 | |
| -4 | -4 | -4 | -4 | |
| -25.65 | -18.00 | -17.85 | -7.50 | |
| 91.9% | 91.9% | 91.9% | 38.6% | |
| -5,059.0% | -5,347.4% | -6,526.4% | -5,937.0% | |
| -5,420.9% | -5,132.6% | -6,092.6% | -5,863.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 12 | 8 | 7 | 8 |
| Cash | 11 | 4 | 4 | 5 |
| Total debt | – | – | – | – |
| Total liabilities | 1 | 2 | 2 | 1 |
| 10 | 6 | 5 | 6 | |
| 0 | 0 | 0 | 1 | |
| -29.8% | -46.4% | -68.9% | -52.5% | |
| -37.8% | -59.9% | -87.3% | -67.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -3 | -3 | -4 | -5 | |
| – | – | – | 1 | |
| -3 | -3 | -4 | -5 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 |
Valuation
- –
- –
- –
- 0.9×
- 59.7×
- –
- –
- -121.7%
- -98.2%
- 0.0%
Profitability
- 38.6%
- -5,937.0%
- -5,863.5%
- -5,709.5%
- -61.5%
- -41.8%
- -83.5%
- -55.6%
- -61.5%
- 2,996.9%
Growth
- +0.0%
- –
- −21.6%
- –
- +45.0%
Financial health
- -1.1×
- 0.00
- 0.0%
- -114.8×
- 11.36
- 11.36
- 0.01
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 3%of 963
Bottom 17%of 908
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.12 | -0.32 | +62.5% |
| Mar 27, 2026 | -0.07 | – | – |
| Nov 13, 2025 | -0.12 | – | – |
| Aug 13, 2025 | -0.19 | – | – |
| May 9, 2025 | -0.23 | – | – |
| Mar 28, 2025 | -0.41 | – | – |
| Nov 12, 2024 | -0.22 | – | – |
| Aug 13, 2024 | -0.31 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
37No pass
Benjamin Graham
69Pass
Philip Fisher
33No pass
Peter Lynch
40No pass
Joel Greenblatt
0No pass
Charlie Munger
42No pass
Terry Smith
42No pass
Questions about Silo Pharma
Is Silo Pharma a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Silo Pharma AI analysis
What does Silo Pharma do?
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It is in Biotechnology.
Does Silo Pharma pay a dividend?
No. Silo Pharma does not pay a dividend at the moment.
Is Silo Pharma stock halal?
No. Silo Pharma does not pass our halal screen: its cash and confirmed interest-bearing investments are 110% of its market value, at or above the 33% limit. How we check
How has Silo Pharma stock done over the past year?
Up 322.7% over the past twelve months, to $1.84. It traded between $0.36 and $9.99 and is 81.6% below its high.
Who are Silo Pharma's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Silo Pharma's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.